Synthesis and biological evaluation of Esaprazole analogues showing σ1 binding and neuroprotective properties in vitro
作者:Nicholas M. Kelly、Anja Wellejus、Heidi Elbrønd-Bek、Morten Sloth Weidner、Signe Humle Jørgensen
DOI:10.1016/j.bmc.2013.02.058
日期:2013.6
surprisingly discovered to have neuroprotectiveactivities and σ1 binding in vitro. A highly diverse set of Esaprazole analogues 2–5 was prepared in order to increase blood–brain barrier penetration. The analogues showed a structure–activity relationship at the σ1 receptor closely matching already published pharmacophores. Many of the analogues were shown to have neuroprotectiveproperties in two assays using
[EN] AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS<br/>[FR] AMINOALCAMIDES POUR UNE UTILISATION DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES, DÉGÉNÉRATIVES OU DÉMYÉLINISANTES DU SYSTÈME NERVEUX CENTRAL
申请人:NENSIUS RES AS
公开号:WO2011000945A9
公开(公告)日:2011-04-07
Compounds for the Treatment of Hepatitis C
申请人:Bender John A.
公开号:US20090130056A1
公开(公告)日:2009-05-21
The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.